Journal: Cancers
Article Title: Conversion of Osteoclasts into Bone-Protective, Tumor-Suppressing Cells
doi: 10.3390/cancers13225593
Figure Lengend Snippet: Conversion of RAW264.7 pre-osteoclasts into iTS cells by the treatment with BML284. CN = control, CM = conditioned medium, RAW = RAW264.7 osteoclasts, MC3T3 = MC3T3 osteoblasts, MSC = mesenchymal stem cells, A5 = MLO-A5 osteocytes, 231 = MDA-MB-231 breast cancer cells, EO = EO771 mammary tumor cells, and 4T1.2 = 4T1.2 mammary tumor cells. ** p < 0.01 vs. CN, while ## p < 0.01 vs. A5 CM. ( A – D ) MTT-based viability of EO771 mammary tumor cells in response to a chemically treated conditioned medium, derived from MLO-A5 osteocytes, MSCs, MC3T3 osteoblasts, and RAW264.7 osteoclasts, respectively. NS = NSC228155 (EGF activator), RC = RCGD423 (JAK/STAT activator), m3 = m-3M3FBS (phospholipase C activator), CW = CW008 (PKA activator), OA = OAC2 (Oct4 activator), YS = YS49 (PI3K activator), and BM = BML284 (Wnt activator). ( E , F ) Tumor selectivity of the inhibitory action of RAW CM, examined tumor selectivity of the inhibitory action using 3 tumor cell lines (MDA-MB-231 breast cancer cell line using 3 tumor cell lines (MDA-MB-231 breast cancer cell line, EO771 mammary tumor cell line, and 4T1.2 mammary tumor cell line), and KTB6 human breast epithelial cells. ( G ) Reduction in PTHrP in BM CM.
Article Snippet: RAW264.7 pre-osteoclast cells, MC3T3 osteoblasts, MSCs, and MLO-A5 osteocyte-like cells were treated with 0.5 μM of NSC228155 (Cayman, Ann Arbor, MI, USA), 20 μM of RCGD423 (Tocris, Minneapolis, MN, USA), 20 μM of m-3M3FBS (Tocris), 20 μM of CW008 (Tocris), 10 μM of OAC2 (MCE, Monmouth Junction, NJ, USA), 50μM of YS49 (MCE), and 0.2 μM of BML284 (Santa Cruz Biotechnology, Dallas, TX, USA) for 1 day.
Techniques: Control, Derivative Assay
Tocris is a verified supplier 
Tocris manufactures this product 
